Exploring the theme of “New Horizons in Biopharma, Biosimilars, & Biologics,” the 4th Edition of the India Biopharma Leaders Conclave (IBLC) convened at Le Meridien, Hyderabad, showcasing a series of dynamic panel discussions on its opening day, June 13th.
A highlight of the event was one of the panel discussions on “Need for R&D in Biosimilars – Entering the Next Phase.” Dr. Ramesh Matur, Senior Vice President of R&D at Biological E Limited, served as the moderator, expertly guiding the discourse on this critical topic. He delved into the strategic future of biosimilar research and development, addressing the myriad challenges and opportunities in this burgeoning sector.
The panel featured distinguished industry veterans, including Dr. TathagataDutta of JODAS EXPOIM Pharmaceuticals, Dr. SreenivasuKarra of CLONZ Biotech, Dr. PratimaSrivastava of Aragen Life Sciences, Dr. SathishSadagopan of Anthem Biosciences, and Dr. KripaMurzello of Bharat Serum & Vaccines Ltd. Each brought their unique perspectives, shaped by decades of experience across various facets of biopharmaceuticals, from clinical trials to gene therapies.
Dr. TathagataDutta commenced the session, emphasizing his rich background in the pharma and biopharma industries and currently leading Jodha’s Expo in Hyderabad. His insights set the stage for a robust discussion on the complex ecosystem of biosimilars and the critical role of R&D in advancing this field.
Dr. SreenivasuKarra highlighted his academic and professional journey from the University of Maryland back to India, where he now leads the R&D team at Clonz Biotech. His opening remarks about the greeting time confusion lightened the mood and underscored the global span of the conference’s attendance.
Dr. PratimaSrivastava shared her extensive experience in drug metabolism and pharmacokinetics, stressing the importance of industry-academia collaborations to drive innovation from laboratory to market. Her international postdoctoral stints have evidently provided her with a valuable perspective on global and local challenges in biosimilar development.
Dr. SathishSadagopan of Anthem Biosciences articulated the developmental milestones of Anthem’s biologicals division and emphasized the critical need for enhancing biologic R&D capabilities to foster innovation and streamline biosimilar production.
Dr. KripaMurzello’s experience at Bharat Serums, spanning two decades, illustrated the long-term commitment required to spearhead advancements in the biological division of a major pharma player.
From ‘Me-Too’ to Global Leader?
The discussion ventured deep into the technological, regulatory, and collaborative challenges facing the biosimilar industry. The panel unanimously agreed that while India has established itself as a formidable player in biosimilars, transitioning from a “me-too” to an innovator status in the global market requires overcoming significant hurdles. These include enhancing regulatory frameworks, bolstering industry-academia partnerships, and investing in cutting-edge research and development.
A critical point of consensus among the panelists was the need for a robust regulatory system that understands and evolves with the technological advancements in biopharma. The lack of regulatory readiness often stymies the development and approval processes, a challenge that Dr. Dutta pointedly criticized, urging for more informed and agile regulatory responses to support innovative biopharma solutions.
Dr. Karra and Dr. Sadagopan stressed the importance of maintaining high standards in clinical trials, a recurring bottleneck for many Indian firms aspiring to global market entry. They discussed the strategic importance of clinical trial design and execution, emphasizing the need for substantial investment and international collaboration to enhance clinical outcomes and market readiness.
The vibrant discussion also touched on the significant role of cutting-edge technologies such as AI and machine learning in transforming R&D processes, from drug discovery through to clinical trials. Dr. Srivastava’s call for increased translational research highlighted the potential of these technologies to streamline development timelines and enhance the efficacy of biosimilars.
As the session wrapped up its insightful session, it was clear that the journey ahead for India’s biopharma sector is both promising and fraught with challenges. The experts concluded that strategic investments in R&D, coupled with regulatory reforms and robust industry-academia collaborations, are pivotal for India to not only continue its leadership in biosimilars but also to pioneer new biologic therapies that meet global standards and patient needs.
In essence, this discussion at the India Biopharma Leaders Conclave not only illuminated the current landscape but also charted a course for the future of biosimilars and biologics, underscoring the imperative for innovation, integration, and international cooperation in this vital sector of healthcare.
– Rashmi Kumari
